Josep Maria Borràs

A US study measures the risk of breast cancer overdiagnosis in screening campaigns for women over 70. These are women who are misdiagnosed with cancer after a mammogram, leading to unnecessary treatments that can cause complications, anxiety and financial costs. The study includes more than 54,000 women over the age of 70 who have had a screening mammogram. The retrospective analysis compares the cumulative incidence of breast cancer between two groups: women who continued screening up to 15 years later, and women who did not. The research estimates that 31% of breast cancer cases in women aged 70-74 result from overdiagnosis: it finds 6.1 cases per 100 women who had continued screening, compared with 4.2 cases per 100 women in the second group. The percentage of overdiagnosis increases with the age of the women. The article is published in the Annals of Internal Medicine, along with an editorial.

A study published in JAMA Network Open has followed 1,340 women with high-risk operable breast cancer. Analysing their lifestyles before, during and after treatment, the researchers conclude that those who followed a healthier pattern - including physical activity, no smoking, high fruit and vegetable intake, and low consumption of meat and sugary drinks - had a 37% lower risk of relapse and a 58% higher chance of survival than those who followed a worse pattern. Although the improvements in absolute risk were much smaller, the authors conclude that "lifestyle interventions may be a safe, inexpensive and feasible adjuvant strategy to delay and prevent recurrence and death from the world's most common cancer".

Un estudio ha estimado las muertes por cáncer que se producirán en la Unión Europea y el Reino Unido en 2023. Comparándolas con las observadas en 2018, estiman que se reducirán en un 6,5 % en hombres y un 3,7 % en mujeres de forma global. Sin embargo, en España aumentará la mortalidad por cáncer de pulmón en mujeres. Los resultados se publican en la revista Annals of Oncology. 

A meta-analysis published in the journal PLOS Medicine has analysed the time to diagnosis and treatment of various types of cancer in rich and poor countries. On average, the processes are 1.5 to 4 times slower in disadvantaged countries.